294 related articles for article (PubMed ID: 26518928)
1. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
3. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
4. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
6. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
7. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.
Budde K; Sommerer C; Rath T; Reinke P; Haller H; Witzke O; Suwelack B; Baeumer D; Sieder C; Porstner M; Arns W
J Nephrol; 2015 Feb; 28(1):115-23. PubMed ID: 25192833
[TBL] [Abstract][Full Text] [Related]
8. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
10. Conversion therapy to everolimus in renal transplant recipients: results after one year.
Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
[TBL] [Abstract][Full Text] [Related]
11. Early Switch to Mammalian Target of Rapamycin Inhibitors Is a Sustainable Treatment Approach in Renal Transplant Recipients: 7-Year Results.
Turunç V; Açıkgöz SB; Dheir H
Transplant Proc; 2019 May; 51(4):1070-1073. PubMed ID: 30981406
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
14. Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.
Badve SV; Pascoe EM; Burke M; Clayton PA; Campbell SB; Hawley CM; Lim WH; McDonald SP; Wong G; Johnson DW
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1845-1855. PubMed ID: 27445164
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in clinical practice in long-term liver transplantation: an observational study.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
17. Low-grade proteinuria and microalbuminuria in renal transplantation.
Halimi JM
Transplantation; 2013 Jul; 96(2):121-30. PubMed ID: 23435457
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of mammalian target of rapamycin inhibitors ab initio after liver transplantation without corticosteroids or induction therapy.
Manzia TM; Angelico R; Toti L; Belardi C; Cillis A; Quaranta C; Tariciotti L; Katari R; Mogul A; Sforza D; Orlando G; Tisone G
Dig Liver Dis; 2016 Mar; 48(3):315-20. PubMed ID: 26682720
[TBL] [Abstract][Full Text] [Related]
19. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
[TBL] [Abstract][Full Text] [Related]
20. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
Paoletti E
Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
